methyl 3-{[3-(1H-imidazol-1-yl)propyl]amino}-2-methylpropanoate, 95.0%, 2g

6-Bromo-2,4-dichloropyrido[2,3-d]pyrimidine, 95+%, 100mg

Microliter syringe GASTIGHT® series 1700 Point type 3, 10 µl, 1701 RNR, 1 piece

5-Bromoindan-2-ol, 95.0%, 1g

7-(3,5-Dimethyl-4-methoxyphenyl)-7-oxoheptanoic acid, 97.0%, 1g

Tert-butyl n-[(2-bromo-5-fluorophenyl)methyl]carbamate, 95%, 100mg

3-Bromo-4-chloro-5-methylpyridine, 95%, 5g

2-(3,4-bis(Allyloxy)phenyl)acetic acid, 97%, 100mg

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-methoxypropanoic acid, 95.0%, 100g

2-Hydroxy-[1,1'-biphenyl]-3-carbaldehyde, 95.0%, 250mg

methyl N-methyl-L-alaninate, 95.0%, 5g

3-Hydroxy-5-(trifluoromethoxy)benzaldehyde, 98%, 250mg

N-[(1-Chloro-4-hydroxy-3-isoquinolinyl)carbonyl]glycine, 99%, 2mg